FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

632 letters match. Newest first.

  1. Aromas Para El Alma S.A.

    Aromas Para El Alma, a Costa Rica drug manufacturer, made EREWHON hand sanitizer/spray subpotent and broke manufacturing rules.

    High risk
  2. EnviroServe Chemicals & Cleaners Ltd.

    EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.

    High risk
  3. Greco Gas, Inc.

    Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.

    High risk
  4. TJA Health, LLC

    FDA warns TJA Health LLC over unsafe drug manufacturing of toothpaste and mouth rinse due to untested components and poor quality control.

    High risk
  5. Avaria Health & Beauty Corp.

    FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.

    High risk
  6. Zydus Lifesciences Limited

    FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.

    High risk
  7. Orean Personal Care Ltd.

    FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.

    High risk
  8. Regenerative Processing Plant, LLC

    FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.

    High risk
  9. Kaylaan LLC

    FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

    High risk
  10. AnuMed International, LLC

    FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.

    High risk
  11. CARsgen Therapeutics Corporation

    FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.

    High risk
  12. EyePoint Pharmaceuticals, Inc.

    FDA cited EyePoint Pharmaceuticals in Watertown, MA for manufacturing-quality violations affecting its YUTIQ eye implant, including inadequate investigations and process controls.

    High risk
  13. Eugia Pharma Specialities Limited

    FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.

    High risk
  14. Intercos Europe S.p.A

    FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.

    High risk
  15. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  16. Nowrez & Ismail Shukri Company

    FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.

    High risk
  17. Central Admixture Pharmacy Services, Inc.

    FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.

    High risk
  18. Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.

    FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.

    High risk
  19. Omega Tech Labs LLC

    Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.

    High risk
  20. Velocity Pharma LLC

    Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.

    High risk
  21. Brassica Pharma Pvt. Ltd.

    FDA warns Brassica Pharma over fabricated sterility and environmental data and poor aseptic controls for sterile drugs.

    High risk
  22. Genuine Virgin Aloe Corp dba Triderma

    FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.

    High risk
  23. Yahon Enterprise Co., Ltd.

    FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.

    High risk
  24. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

    FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.

    High risk
  25. YangZhou SuXiang Medical Instrument Co., Ltd.

    FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.

    High risk
  26. Max Chemical Inc.

    FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.

    High risk
  27. ARG Laboratories, Inc.

    FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.

    High risk
  28. Art of Beauty Company, Inc.

    FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.

    High risk
  29. reBom Co., Ltd.

    reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.

    High risk
  30. Optikem International Inc.

    FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.

    High risk
  31. Laboratorio Magnachem International

    FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

    High risk
  32. Sun Pharmaceutical Industries Limited

    FDA cited Sun Pharmaceutical Industries for inadequate cleaning and maintenance at its Dadra drug plant, risking cross-contamination, and for weak investigations.

    High risk
  33. Sani-Care Salon Products, Inc.

    FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.

    High risk
  34. GFA Production Xiamen Co., Ltd.

    GFA Production Xiamen failed CGMP for drugs, including process validation, cleaning, and lab controls.

    High risk
  35. Landy International

    FDA found Landy International’s OTC hand sanitizers adulterated after a 2023 inspection revealed missing testing, unsafe water, and data integrity failures.

    High risk
  36. Aqualex Co., Ltd.

    Aqualex, a Korean contract manufacturer, was cited for manufacturing failures and an unapproved OTC sunscreen with misleading labeling.

    High risk
  37. TCT Nutraceuticals SDN. BHD

    FDA warns TCT Nutraceuticals over manufacturing-rule failures in OTC hand sanitizer, including no methanol testing.

    High risk
  38. Fancystage Unipessoal, LDA

    FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.

    High risk
  39. Cosmetic Solutions, LLC

    FDA warns Cosmetic Solutions over manufacturing failures and unapproved OTC drugs at Boca Raton plant.

    High risk
  40. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  41. Biomic Sciences, LLC dba ION Intelligence of Nature

    Biomic Sciences' nasal spray was grossly contaminated with microorganisms, and FDA also found manufacturing and labeling violations.

    High risk
  42. Safari Stem Cell, LLC

    FDA warned Safari Stem Cell for selling unapproved stem cell animal drugs made without required CGMP controls, including sterility testing.

    High risk
  43. Seatex, LLC

    FDA: Seatex made hand sanitizer on equipment also used for floor cleaner and skipped ingredient identity tests.

    High risk
  44. Central Admixture Pharmacy Services, Inc.

    FDA warned sterile drug compounder Central Admixture Pharmacy Services (Phoenix) that dirty areas and weak sterility testing made its drugs adulterated.

    High risk
  45. Natuzen Co., Ltd.

    Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.

    High risk
  46. Grupo Quimico SRL

    FDA warns Uruguay contract testing lab Grupo Quimico over data integrity failures, including unreported failing HPLC results.

    High risk
  47. Westwood Laboratories LLC

    FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

    High risk
  48. Cohere Beauty

    FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.

    Medium
  49. Seatex, LLC

    Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.

    High risk
  50. Central Admixture Pharmacy Services, Inc.

    FDA warned Central Admixture Pharmacy Services' Allentown outsourcing facility over sterile drug contamination and CGMP failures.

    High risk